261 related articles for article (PubMed ID: 10658525)
41. Bimonthly high dose leucovorin and 5-fluorouracil 48-hour continuous infusion in patients with advanced colorectal carcinoma. Groupe d'Etude et de Recherche sur les Cancers de l'Ovaire et Digestifs (GERCOD).
Beerblock K; Rinaldi Y; André T; Louvet C; Raymond E; Tournigand C; Carola E; Favre R; de Gramont A; Krulik M
Cancer; 1997 Mar; 79(6):1100-5. PubMed ID: 9070486
[TBL] [Abstract][Full Text] [Related]
42. Increased tolerability of bimonthly 12-hour timed flat infusion 5-fluorouracil/irinotecan regimen in advanced colorectal cancer: A dose-finding study.
Ficorella C; Ricevuto E; Morelli MF; Morese R; Cannita K; Cianci G; Porzio G; Di Rocco ZC; De Galitiis F; De Tursi M; Tinari N; Iacobelli S; Marchetti P
Oncol Rep; 2006 May; 15(5):1345-50. PubMed ID: 16596209
[TBL] [Abstract][Full Text] [Related]
43. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer.
de Gramont A; Vignoud J; Tournigand C; Louvet C; André T; Varette C; Raymond E; Moreau S; Le Bail N; Krulik M
Eur J Cancer; 1997 Feb; 33(2):214-9. PubMed ID: 9135491
[TBL] [Abstract][Full Text] [Related]
44. A randomized phase II trial of pemetrexed plus irinotecan (ALIRI) versus leucovorin-modulated 5-FU plus irinotecan (FOLFIRI) in first-line treatment of locally advanced or metastatic colorectal cancer.
Underhill C; Goldstein D; Gorbounova VA; Biakhov MY; Bazin IS; Granov DA; Hossain AM; Blatter J; Kaiser C; Ma D
Oncology; 2007; 73(1-2):9-20. PubMed ID: 18334829
[TBL] [Abstract][Full Text] [Related]
45. Safety and antitumor activity of arsenic trioxide plus infusional 5-fluorouracil, leucovorin, and irinotecan as second-line chemotherapy for refractory metastatic colorectal cancer: A pilot study from South India.
Lakshmaiah KC; Chaudhuri T; Babu GK; Lokanatha D; Jacob LA; Suresh Babu MC; Rudresha AH; Lokesh KN; Rajeev LK
Indian J Cancer; 2017; 54(4):631-633. PubMed ID: 30082548
[TBL] [Abstract][Full Text] [Related]
46. Triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: a multicenter phase II trial.
Souglakos J; Mavroudis D; Kakolyris S; Kourousis Ch; Vardakis N; Androulakis N; Agelaki S; Kalbakis K; Tsetis D; Athanasiadis N; Samonis G; Georgoulias V
J Clin Oncol; 2002 Jun; 20(11):2651-7. PubMed ID: 12039926
[TBL] [Abstract][Full Text] [Related]
47. Weekly oxaliplatin, high-dose folinic acid and 24h-5-fluorouracil (FUFOX) as salvage therapy in metastatic colorectal cancer patients pretreated with irinotecan and folinic acid/5-fluorouracil regimens.
Moehler M; Hoffmann T; Hildner K; Siebler J; Galle PR; Heike M
Z Gastroenterol; 2002 Dec; 40(12):957-64. PubMed ID: 12564419
[TBL] [Abstract][Full Text] [Related]
48. Retrospective comparison of two different schedules of irinotecan, 5-fluorouracil and folinic acid in previously untreated patients with advanced colorectal carcinoma: a single institution experience.
Gluzman A; Rubinov K; Mermershtain W; Man S; Ariad S; Lavrenkov K
J Chemother; 2007 Dec; 19(6):739-43. PubMed ID: 18230559
[TBL] [Abstract][Full Text] [Related]
49. Multicentre phase II study using increasing doses of irinotecan combined with a simplified LV5FU2 regimen in metastatic colorectal cancer.
Duffour J; Gourgou S; Desseigne F; Debrigode C; Mineur L; Pinguet F; Poujol S; Chalbos P; Bressole F; Ychou M
Cancer Chemother Pharmacol; 2007 Aug; 60(3):383-9. PubMed ID: 17124595
[TBL] [Abstract][Full Text] [Related]
50. A phase II study of FOLFIRI-3 (double infusion of irinotecan combined with LV5FU) after FOLFOX in advanced colorectal cancer patients.
Mabro M; Artru P; André T; Flesch M; Maindrault-Goebel F; Landi B; Lledo G; Plantade A; Louvet C; de Gramont A
Br J Cancer; 2006 May; 94(9):1287-92. PubMed ID: 16622455
[TBL] [Abstract][Full Text] [Related]
51. A retrospective study of bifractionated CPT-11 with LF5FU infusion (FOLFIRI-3) in colorectal cancer patients pretreated with oxaliplatin and CPT-11 containing chemotherapies.
Viel E; Demarchi MF; Chaigneau L; Nguyen T; Legat C; Stein U; Thiery-Vuillemin A; Limat S; Pivot X; Borg C
Am J Clin Oncol; 2008 Feb; 31(1):89-94. PubMed ID: 18376234
[TBL] [Abstract][Full Text] [Related]
52. Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen.
André T; Bensmaine MA; Louvet C; François E; Lucas V; Desseigne F; Beerblock K; Bouché O; Carola E; Merrouche Y; Morvan F; Dupont-André G; de Gramont A
J Clin Oncol; 1999 Nov; 17(11):3560-8. PubMed ID: 10550155
[TBL] [Abstract][Full Text] [Related]
53. Irinotecan (CPT-11) combined with bolus 5-fluorouracil/leucovorin (Saltz regimen) as first-line chemotherapy of patients with advanced colorectal cancer.
Barceló R; López Vivanco G; Rivera F; GarcíaGirón C; Alonso M; Castañón C; Ramos M; Navalón M; Centelles M; Balcells M
Anticancer Drugs; 2006 Jan; 17(1):89-94. PubMed ID: 16317295
[TBL] [Abstract][Full Text] [Related]
54. Multicenter phase II study of CPT-11 fractionated over two days with bimonthly leucovorin and 5-fluorouracil in patients with metastatic colorectal cancer.
Recchia F; Nuzzo A; Lalli A; Di Lullo L; De Filippis S; Saggio G; Di Blasio A; Rea S
Anticancer Res; 2003; 23(3C):2903-8. PubMed ID: 12926132
[TBL] [Abstract][Full Text] [Related]
55. Decreasing dosage of irinotecan, 5-flurouracil (5-FU) and leucovorin (LV) in the treatment of advanced and/or metastatic colorectal cancer: a phase II study.
Huang JS; Yen CL; You YT; Wang CH; Lan YJ; Lai CH; Chueh TC; Liaw CC
Chang Gung Med J; 2006; 29(3):297-305. PubMed ID: 16924892
[TBL] [Abstract][Full Text] [Related]
56. Irinotecan (CPT11) plus high-dose 5-fluorouracil (5-FU) and leucovorin (LV) as salvage therapy for metastatic colorectal cancer (MCRC) after failed oxaliplatin plus 5-FU and LV: a pilot study in Taiwan.
Tai CJ; Liu JH; Chen WS; Lin JK; Wang WS; Yen CC; Chiou TJ; Chen PM
Jpn J Clin Oncol; 2003 Mar; 33(3):136-40. PubMed ID: 12672791
[TBL] [Abstract][Full Text] [Related]
57. [FOLFIRI regimen for metastatic or recurrent colorectal cancer].
Uemura N; Yamada Y
Gan To Kagaku Ryoho; 2006 Jul; 33(7):904-6. PubMed ID: 16835477
[TBL] [Abstract][Full Text] [Related]
58. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.
Cremolini C; Loupakis F; Antoniotti C; Lupi C; Sensi E; Lonardi S; Mezi S; Tomasello G; Ronzoni M; Zaniboni A; Tonini G; Carlomagno C; Allegrini G; Chiara S; D'Amico M; Granetto C; Cazzaniga M; Boni L; Fontanini G; Falcone A
Lancet Oncol; 2015 Oct; 16(13):1306-15. PubMed ID: 26338525
[TBL] [Abstract][Full Text] [Related]
59. High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7).
Maindrault-Goebel F; de Gramont A; Louvet C; André T; Carola E; Mabro M; Artru P; Gilles V; Lotz JP; Izrael V; Krulik M;
Eur J Cancer; 2001 May; 37(8):1000-5. PubMed ID: 11334725
[TBL] [Abstract][Full Text] [Related]
60. Protracted continuous infusion of 5-fluorouracil and low-dose leucovorin in patients with metastatic colorectal cancer resistant to 5-fluorouracil bolus-based chemotherapy: a phase II study.
Falcone A; Allegrini G; Lencioni M; Pfanner E; Brunetti I; Cianci C; Galli C; Masi G; Antonuzzo A; Conte P
Cancer Chemother Pharmacol; 1999; 44(2):159-63. PubMed ID: 10412951
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]